FDA Expands Approval of Osimertinib in Lung Cancer
MedPage Today) — The FDA has approved osimertinib (Tagrisso) for locally advanced, unresectable stage III non-small cell lung cancer (NSCLC) following chemoradiotherapy, the agency announced Wednesday. The EGFR inhibitor is specifically indicated…
MedPage Today) — The FDA has approved osimertinib (Tagrisso) for locally advanced, unresectable stage III non-small cell lung cancer (NSCLC) following chemoradiotherapy, the agency announced Wednesday.
The EGFR inhibitor is specifically indicated…
Read More
About Author
